新华财经上海11月8日电（记者王淑娟）作为推动高水平对外开放的重要平台，进博会上的医疗器械及 医药保健展区每届都汇聚了全球顶尖医疗科技企业，集中展示前沿医疗创新成果。不少跨国制药和器械 公司都是进博会的八年"全勤生"。今年有哪些新风向？ 通过进博会这个前沿医疗创新成果亮相的窗口，可以看到，进博会的"溢出效应"持续改写创新药进入中 国市场的速度。8年间，不少创新药物依托进博会的平台实现"华丽转身"，加速走进中国患者的生活。 我国上半年批准创新药43个、创新医疗器械45个，同比分别增长59%和87%，政策红利正在转化为产业 发展动力。这一趋势在第八届进博会上得到集中体现。 值得关注的是，国家医保局首次在进博会设展，主题为"中国医保，全球医药重要采购方"，展示医保超 大规模覆盖与采购成果，以及对全球创新药械的持续购买和支持医药创新的立场。 赛诺菲已是第八年参加进博会，其展品"达必妥"（度普利尤单抗注射液）是进博会溢出效应的最佳见证 者。这款药物从首次亮相、获批上市到纳入国家医保目录，再到不断拓展新适应症，经历了进博会的全 流程催化。 默沙东在第八届进博会上展示了其在中国境内已获批的约30种药物和疫苗，覆盖肿瘤、抗感 ...

Core Insights - A strategic cooperation framework agreement was signed among Ping An Health Insurance, Peking University Health Management Group, and Roche Pharmaceuticals China to launch the "Pharmaceutical Insurance" ecosystem by 2025 [1][4] Group 1: Strategic Cooperation - The signing ceremony was attended by key executives from all three companies, highlighting the collaborative effort in the healthcare sector [3] - The partnership aims to leverage each company's strengths: Roche's innovative drug development, Peking University's medical service network, and Ping An's insurance and health management services [4][5] Group 2: Policy Alignment - The initiative aligns with China's 14th Five-Year Plan, which emphasizes deepening healthcare reform and enhancing insurance support for the health industry [4] - The collaboration focuses on critical disease areas such as oncology, aiming to create a comprehensive health service system that spans disease prevention, precise diagnosis, innovative treatment, and health insurance services [4] Group 3: Value-Based Healthcare - The partnership seeks to establish a new paradigm of value-based healthcare, contributing to the "Healthy China" strategy by providing integrated health services throughout the customer lifecycle [5][7] - Ping An Health Insurance has recently upgraded its "Ping An Happy Health" platform, which integrates various health management services to support the new "Pharmaceutical Insurance" model [7]

Core Insights - The health insurance premium income for life insurance companies reached 578.4 billion yuan, a year-on-year increase of 0.5%, while property insurance companies reported 181.5 billion yuan, a growth of 8.9%, leading to a total health insurance premium income of 759.9 billion yuan, up 2.4% year-on-year [1][2] Group 1: Market Trends - The growth rate of health insurance premiums has slowed to 2.4% in the first eight months of the year, attributed to consumer tendencies to cut non-essential spending, product homogeneity, and competition from public health insurance [2][3] - The disparity in growth rates between life and property insurance companies is notable, with property insurance companies showing a higher growth rate due to their focus on short-term products and innovative offerings [3] Group 2: Long-term Potential - Experts remain optimistic about the long-term growth potential of health insurance, driven by factors such as an aging population and increasing health awareness among residents [3][4] - The integration of commercial health insurance into a multi-payment system is encouraged by policies, providing opportunities for product innovation and industry collaboration [3][4] Group 3: Role of Multi-Payment Platforms - Multi-payment platforms, such as Shanghai Meixin Health Technology Group, are enhancing the efficiency and value of health insurance services through innovative payment models and comprehensive service systems [4][5] - These platforms are crucial in connecting medical, pharmaceutical, and insurance sectors, reflecting the ongoing development of the "medical insurance" ecosystem [4][5] Group 4: Industry Development - The growth of multi-payment platforms supports the healthy development of both the insurance and pharmaceutical industries by filling coverage gaps and improving patient payment capabilities [5][6] - These platforms are becoming essential links in enhancing the accessibility of innovative medical products and improving the overall healthcare experience for patients [6]

Core Viewpoint - The recent "AI FOR HEALTH" industry ecosystem cooperation conference hosted by Meixin Health focused on the integration of medical insurance and pharmaceuticals in the context of a diversified payment era, addressing long-standing issues in the healthcare system in China [1][2]. Group 1: Conference Highlights - The conference featured two main sections: "Product Upgrades and Industry Solution Sharing" and "Payment Innovation and Ecological Collaboration Forum," bringing together leaders from insurance companies, pharmaceutical firms, industry experts, and strategic partners [1]. - Meixin Health's CEO, Zhang Xiaodong, emphasized the need to address the misallocation of quality medical resources, cumbersome medical processes, and fragmented payment tools, which hinder access to innovative pharmaceuticals and healthcare [1]. Group 2: Industry Insights - Experts highlighted the challenges in integrating medical insurance and pharmaceuticals, noting that policy coordination is essential to provide health products and services effectively [2]. - The current commercial health insurance primarily focuses on sales and post-disease economic compensation, lacking true involvement in medical risk control, which limits its effectiveness [2]. - The collaboration between medical institutions, commercial insurance, and pharmaceutical companies is crucial for designing diversified insurance products that can enhance healthcare access for a broader population [2]. Group 3: Future Outlook - With the aging population and increasing medical demands, the industry must embrace long-termism and innovation to advance together [2]. - The integration of payment innovations that genuinely serve patient needs and ecological collaboration focused on value creation will propel the Chinese healthcare industry towards high-quality development [2].